Predict your next investment

HEALTHCARE | Medical Devices & Equipment / Surgical Devices

See what CB Insights has to offer

Stage

Acq - P2P | Acquired

Total Raised

$18.51M

Valuation

$0000 

About Fusion Medical Technologies

Fusion is developing surgical sealants for procedures which initially include those in cardiovascular, vascular, orthopedics, and neurosurgery specialties. Acquired by Baxter BioScience.

Fusion Medical Technologies Headquarter Location

34175 Ardenwood Blvd.

Fremont, California, 94555,

United States

510-818-4600

Latest Fusion Medical Technologies News

Baxter Completes Acquisition of Fusion Medical Technologies

May 13, 2016

Broad Clinical Applications of Fusion's Hemostat Complements Baxter's Strength in Tissue Sealing and Expands Surgical Channels May 03, 2002, 01:00 ET from Baxter International Inc. DEERFIELD, Ill., May 3 /PRNewswire-FirstCall/ -- Baxter International Inc. (NYSE: BAX) announced today that it has completed its acquisition of Fusion Medical Technologies (Nasdaq: FSON) for approximately $157 million of Baxter common stock in a stock-for-stock merger. Baxter has begun the process of integrating Fusion and anticipates a seamless transition for customers and its approximately 100 employees. "By joining forces with Fusion, Baxter takes another step forward in playing a broader and more vital role in the biosurgery market," said Greg Bosch, general manager of Baxter's BioSurgery business, noting Fusion's expertise in developing and commercializing proprietary products used to control bleeding during surgery. "We believe that Fusion's talents and expertise in collagen/gelatin-based products complement our strategic focus on providing innovative therapeutic solutions for biosurgery and tissue regeneration. Most importantly, we believe that combining the businesses should accelerate the clinical adoption of both Tisseel fibrin sealant and FloSeal matrix hemostatic sealant, for the ultimate benefit of patients worldwide. " Fusion's primary commercial product, FloSeal matrix, is a combination of specially engineered collagen-derived particles and topical thrombin that is very effective in controlling bleeding. It is easy to use and works well on wet, actively bleeding tissue, even in very challenging situations. The FDA approved the sale of FloSeal in the United States in December 1999. Fusion currently markets the FloSeal products in surgical procedures, other than ophthalmic, as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical. Tisseel VH fibrin sealant, Baxter's principal biosurgery product, was the first fibrin sealant to receive FDA approval and is indicated for tissue sealing, as well as hemostasis in cardiopulmonary procedures. Introduced in Europe, Tisseel (also marketed as Tissucol fibrin sealant in some countries) is backed by more than twenty-two years of clinical experience and has been used in more than 8 million surgical procedures worldwide. Baxter's BioScience business develops and produces biopharmaceuticals, vaccines, and innovative therapeutic solutions for biosurgery and tissue regeneration, including fibrin sealant and a complete line of application devices. Baxter International Inc. is a global health care company that, through its subsidiaries, provides critical therapies for people with life-threatening conditions. Baxter's bioscience, medication delivery and renal products and services are used to treat patients with some of the most challenging medical conditions including cancer, hemophilia, immune deficiencies, infectious diseases, kidney disease and trauma. (Tisseel and Tissucol are trademarks of Baxter International Inc. or Baxter AG. Tisseel is registered in the U.S. Patent and Trademark office. ) (Fusion Medical Technologies, Fusion, FloSeal, and the stylized Fusion logo are trademarks of Fusion. ) This press release contains forward-looking statements that involve risks and uncertainties, including technological advances in the medical field, product demand and market acceptance, the effect of economic conditions, the impact of competitive products and pricing, actions of regulatory bodies and other risks detailed in the company's filings with the SEC. These forward- looking statements are based on estimates and assumptions made by management of Baxter at the time of issuance of this press release, that are believed to be reasonable, but are inherently uncertain and difficult to predict. Actual results or experience could differ materially from the forward-looking statements. MAKE YOUR OPINION COUNT - Click Here http://tbutton.prnewswire.com/prn/11690X13944352 SOURCE Baxter International Inc.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Fusion Medical Technologies

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Fusion Medical Technologies is included in 1 Expert Collection, including Neuroscience.

N

Neuroscience

2,144 items

Companies developing products that monitor, analyze, protect, or otherwise influence the structure/function of the nervous system.

Fusion Medical Technologies Patents

Fusion Medical Technologies has filed 3 patents.

The 3 most popular patent topics include:

  • Coagulopathies
  • Hematology
  • Systemic risk
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/21/2017

7/28/2020

Vascular diseases, Hematology, Interventional radiology, Systemic risk, Coagulopathies

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

12/21/2017

00/00/0000

00/00/0000

Grant Date

7/28/2020

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Related Topics

Vascular diseases, Hematology, Interventional radiology, Systemic risk, Coagulopathies

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.